Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul

被引:17
作者
Alpsar, Dilek [1 ]
Agacfidan, Ali [1 ]
Luebke, Nadine [2 ]
Verheyen, Jens [2 ]
Eraksoy, Haluk [3 ]
Cagatay, Atahan [3 ]
Bozkaya, Emel [1 ]
Kaiser, Rolf [2 ]
Akguel, Baki [2 ]
机构
[1] Istanbul Univ, Dept Microbiol & Clin Microbiol, Istanbul Fac Med, Istanbul, Turkey
[2] Univ Cologne, Inst Virol, D-50935 Cologne, Germany
[3] Istanbul Univ, Dept Infect Dis, Istanbul Fac Med, Istanbul, Turkey
关键词
HIV-1; Antiretroviral drug resistance; Epidemiology; Ethnic group; IMMUNODEFICIENCY-VIRUS TYPE-1; 1ST-LINE ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE; GENETIC SUBTYPES; MUTATIONS; COMBINATION; PREVALENCE; INHIBITORS; INITIATION; EFAVIRENZ;
D O I
10.1007/s00430-012-0285-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In Turkey, the first HIV/AIDS case was reported in 1985. Since then the number of persons with HIV infection has increased, HIV is getting a public health problem. The aim of this study was to determine HIV-1 subtype diversity, drug resistance and gag cleavage site mutations among 20 HIV-infected men having sex with men from Istanbul, Turkey. The most prevalent subtype was found to be subtype B (50 %), but also the non-B subtypes A1, C and CRF02_AG, CRF03_AB and CRF06_cpx were found. Resistance-associated mutations were found in 6 patients (30 %) with 2/6 patients being therapy-experienced and 4/6 therapy-na < ve at the time-point of analysis. In these patients, the nucleoside reverse transcriptase inhibitor (NRTI)-associated resistance mutations M41L, T215C, V75I, T69N, the non-NRTI associated mutations V106I, E138A, K103N and the protease inhibitor associated mutations Q58E and V82I were detected. Two virus strains also presented Gag cleavage site mutations. With increasing numbers of HIV-infected Turkish patients that require anti-retroviral treatment, HIV-1 drug-resistance testing is strongly recommended in order to choose the most active drug combination for therapy to achieve better clinical outcomes.
引用
收藏
页码:251 / 255
页数:5
相关论文
共 28 条
[1]   Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy [J].
Bacheler, LT ;
Anton, ED ;
Kudish, P ;
Baker, D ;
Bunville, J ;
Krakowski, K ;
Bolling, L ;
Aujay, M ;
Wang, XV ;
Ellis, D ;
Becker, MF ;
Lasut, AL ;
George, HJ ;
Spalding, DR ;
Hollis, G ;
Abremski, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2475-2484
[2]   Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme [J].
Bellocchi, MC ;
Forbici, F ;
Palombi, L ;
Gori, C ;
Coelho, E ;
Svicher, V ;
D'Arrigo, R ;
Emberti-Gialloreti, L ;
Ceffa, S ;
Erba, F ;
Marazzi, MC ;
Silberstein, FC ;
Perno, CF .
JOURNAL OF MEDICAL VIROLOGY, 2005, 76 (04) :452-458
[3]   Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine [J].
Coakley, EP ;
Gillis, JM ;
Hammer, SM .
AIDS, 2000, 14 (02) :F9-F15
[4]   Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but Not Etravirine [J].
Gatanaga, Hiroyuki ;
Ode, Hirotaka ;
Hachiya, Atsuko ;
Hayashida, Tsunefusa ;
Sato, Hironori ;
Oka, Shinichi .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (04) :1596-1602
[5]   Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004 [J].
Hemelaar, Joris ;
Gouws, Eleanor ;
Ghys, Peter D. ;
Osmanov, Saladin .
AIDS, 2006, 20 (16) :W13-W23
[6]   Profile of HIV/AIDS Patients in a Tertiary Hospital in Istanbul, Turkey [J].
Karaosmanoglu, Hayat Kumbasar ;
Aydin, Ozlem Altuntas ;
Nazlican, Ozcan .
HIV CLINICAL TRIALS, 2011, 12 (02) :104-108
[7]   5TH MUTATION IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE CONTRIBUTES TO THE DEVELOPMENT OF HIGH-LEVEL RESISTANCE TO ZIDOVUDINE [J].
KELLAM, P ;
BOUCHER, CAB ;
LARDER, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1934-1938
[8]   Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency [J].
Klabe, RM ;
Bacheler, LT ;
Ala, PJ ;
Erickson-Viitanen, S ;
Meek, JL .
BIOCHEMISTRY, 1998, 37 (24) :8735-8742
[9]  
Koh Y., 2007, 14 C RETR OPP INF LO
[10]   Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients [J].
Marcelin, Anne-Genevieve ;
Flandre, Philippe ;
Descamps, Diane ;
Morand-Joubert, Laurence ;
Charpentier, Charlotte ;
Izopet, Jacques ;
Trabaud, Mary-Anne ;
Saoudin, Henia ;
Delaugerre, Constance ;
Tamalet, Catherine ;
Cottalorda, Jacqueline ;
Bouvier-Alias, Magali ;
Bettinger, Dominique ;
Dos Santos, Georges ;
Ruffault, Annick ;
Alloui, Chakib ;
Henquell, Cecile ;
Rogez, Sylvie ;
Barin, Francis ;
Signori-Schmuck, Anne ;
Vallet, Sophie ;
Masquelier, Bernard ;
Calvez, Vincent .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) :72-77